Top Page
Circassia Pharmaceuticals
(LSE:NIOX)
Circassia Pharmaceuticals (NIOX) vs. S&P 500 (SPY)
Circassia Pharmaceuticals Business Overview & Revenue Model
Circassia Pharmaceuticals Financial Statement Overview
| Breakdown | |||||
| TTM | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 48.00M | 36.80M | 31.30M | 27.90M | 23.90M | 34.60M | Gross Profit |
| 34.40M | 26.50M | 22.20M | 19.00M | 16.30M | 25.50M | EBIT |
| 6.60M | 4.60M | 1.80M | -4.30M | -17.30M | -18.50M | EBITDA |
| 11.20M | 8.70M | 15.40M | 3.10M | -9.10M | -12.10M | Net Income Common Stockholders |
| 14.30M | 10.70M | 16.10M | 3.60M | -33.50M | -16.80M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 19.90M | 19.90M | 19.40M | 12.60M | 7.40M | 27.00M | Total Assets |
| 91.50M | 91.50M | 98.50M | 86.40M | 103.10M | 246.80M | Total Debt |
| 1.10M | 1.10M | 1.00M | 1.30M | 1.60M | 111.40M | Net Debt |
| -18.80M | -18.80M | -18.40M | -11.30M | -5.80M | 84.40M | Total Liabilities |
| 7.70M | 7.70M | 16.60M | 19.60M | 37.00M | 162.00M | Stockholders Equity |
| 83.80M | 83.80M | 81.90M | 66.80M | 66.10M | 84.80M |
| Cash Flow | Free Cash Flow | ||||
| 15.70M | 11.30M | 6.60M | 1.20M | -24.40M | -25.40M | Operating Cash Flow |
| 15.80M | 11.60M | 6.70M | 1.40M | -23.90M | -25.10M | Investing Cash Flow |
| -600.00K | -300.00K | -100.00K | -200.00K | -500.00K | -9.90M | Financing Cash Flow |
| -19.50M | -10.50M | -500.00K | 4.10M | 4.30M | 21.90M |
Circassia Pharmaceuticals Technical Analysis
Circassia Pharmaceuticals Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
71 Outperform | £271.56M | 77.27 | 4.55% | 1.47% | 13.59% | -66.27% | |
59 Neutral | £349.75M | ― | -5.04% | ― | -1.02% | 67.70% | |
56 Neutral | £295.91M | 7.43 | 11.74% | ― | 38.80% | ― | |
52 Neutral | $5.22B | 3.55 | -44.39% | 2.82% | 15.40% | -0.09% | |
49 Neutral | $312.70M | ― | -66.23% | ― | 43.84% | 74.88% | |
48 Neutral | £338.42M | ― | -369.20% | ― | 4.50% | 74.32% |
Circassia Pharmaceuticals Corporate Events
NIOX Group plc reported a strong start to 2025 with a 21% increase in sales, driven by significant growth in its research business due to increased clinical trial activity. The company is prioritizing the expansion of FeNO testing in the US, the launch of the NIOX PRO® device, and the development of a home-use device. Despite a one-off cost from a withdrawn bid and upcoming board changes, NIOX remains optimistic about its financial health and strategic direction.
The most recent analyst rating on (GB:NIOX) stock is a Buy with a £77.00 price target. To see the full list of analyst forecasts on Circassia Pharmaceuticals stock, see the GB:NIOX Stock Forecast page.
Spark’s Take on GB:NIOX Stock
According to Spark, TipRanks’ AI Analyst, GB:NIOX is a Outperform.
Circassia Pharmaceuticals is in a strong financial position with robust revenue growth and effective cash flow management. However, fluctuations in net profit margins and ROE, along with a high P/E ratio, present some risks. Technical indicators suggest mixed market signals, while corporate events highlight strategic growth and expansion opportunities. Overall, the stock is well-positioned, although high valuation could limit its upside potential.
To see Spark’s full report on GB:NIOX stock, click here.
NIOX Group plc, a company listed on the AIM market, has announced a timetable for its proposed final dividend for the financial year ending 31 December 2024. The dividend of 1.25 pence per share is subject to approval at the Annual General Meeting on 14 May 2025, with key dates including an ex-dividend date of 15 May 2025 and a payment date of 16 June 2025.
Spark’s Take on GB:NIOX Stock
According to Spark, TipRanks’ AI Analyst, GB:NIOX is a Neutral.
Circassia Pharmaceuticals shows strong financial performance with robust revenue growth and cash flow management. However, technical analysis suggests a bearish trend, and the high P/E ratio raises valuation concerns. Recent corporate events reflect strategic growth but also highlight uncertainties. Overall, the stock is positioned for growth with caution advised due to valuation and technical indicators.
To see Spark’s full report on GB:NIOX stock, click here.
NIOX Group plc, a company listed on the AIM market, has announced the publication of its Notice of the 2025 Annual General Meeting on its website. The meeting is scheduled for May 14, 2025, at their registered office in Oxford, England, and shareholders have been sent copies of the 2024 Annual Report and Accounts if requested.
Spark’s Take on GB:NIOX Stock
According to Spark, TipRanks’ AI Analyst, GB:NIOX is a Neutral.
Circassia Pharmaceuticals exhibits a solid financial foundation with strong revenue and cash flow growth. The technical analysis indicates positive momentum but is limited by incomplete indicators. The high P/E ratio suggests overvaluation, posing some risk. Recent corporate events highlight strategic growth but also introduce uncertainty. Overall, the stock is positioned well within the industry, but potential investors should be cautious of the high valuation and strategic uncertainties.
To see Spark’s full report on GB:NIOX stock, click here.
Niox Group PLC, a UK-based company, has announced a change in the breakdown of its voting rights due to an acquisition or disposal of financial instruments. Spreadex LTD, a regulated provider of spread betting and CFD trading, has adjusted its position in Niox Group, resulting in a decrease in its voting rights from 3.0694% to 2.4063%. This adjustment reflects a shift in the financial instruments held by Spreadex, impacting the overall voting influence within Niox Group.
Spark’s Take on GB:NIOX Stock
According to Spark, TipRanks’ AI Analyst, GB:NIOX is a Neutral.
Circassia Pharmaceuticals exhibits a solid financial foundation with strong revenue and cash flow growth. The technical analysis indicates positive momentum but is limited by incomplete indicators. The high P/E ratio suggests overvaluation, posing some risk. Recent corporate events highlight strategic growth but also introduce uncertainty. Overall, the stock is positioned well within the industry, but potential investors should be cautious of the high valuation and strategic uncertainties.
To see Spark’s full report on GB:NIOX stock, click here.
NIOX Group plc, a company listed on the AIM market, announced a transaction involving Áinne Naylor, a Person Closely Associated with Robert Naylor, a Non-Executive Director. Áinne Naylor purchased 44,166 Ordinary Shares at £0.565 per share, increasing Robert Naylor’s total shareholding to 44,166 shares, representing 0.01% of the company’s voting rights. This transaction is part of the company’s ongoing compliance with UK MAR regulations, ensuring transparency in managerial transactions.
Spark’s Take on GB:NIOX Stock
According to Spark, TipRanks’ AI Analyst, GB:NIOX is a Outperform.
Circassia Pharmaceuticals shows strong financial performance with robust revenue growth and cash flow management, although some concerns exist around net profit margin volatility and ROE. Technical analysis suggests upward momentum, but high P/E ratio raises valuation concerns. Corporate events indicate strategic growth and potential acquisition, enhancing future prospects. Overall, the stock is well-positioned but with some valuation reservations.
To see Spark’s full report on GB:NIOX stock, click here.
NIOX Group PLC, a company in the pharmaceutical industry, has announced that Keensight Capital will not make a firm offer for the company due to current macroeconomic conditions. Consequently, NIOX has decided to discontinue its Private Sale Process, as it is unlikely to achieve optimal outcomes for shareholders. Despite these developments, NIOX reported an 18% sales growth in the first quarter of the year and a net cash position of £15.4 million as of March 31, 2025.
Spark’s Take on GB:NIOX Stock
According to Spark, TipRanks’ AI Analyst, GB:NIOX is a Outperform.
Circassia Pharmaceuticals shows strong financial performance with robust revenue growth and cash flow management, although some concerns exist around net profit margin volatility and ROE. Technical analysis suggests upward momentum, but high P/E ratio raises valuation concerns. Corporate events indicate strategic growth and potential acquisition, enhancing future prospects. Overall, the stock is well-positioned but with some valuation reservations.
To see Spark’s full report on GB:NIOX stock, click here.
NIOX Group plc, a company involved in the healthcare sector, has applied for a block admission of 6,862,848 ordinary shares to be traded on AIM at the London Stock Exchange. This move is part of the company’s 2022 Performance Share Plan Scheme, and the shares are expected to be admitted by 16 April 2025, aligning with existing shares and potentially impacting the company’s market presence.
Spark’s Take on GB:NIOX Stock
According to Spark, TipRanks’ AI Analyst, GB:NIOX is a Outperform.
Circassia Pharmaceuticals shows strong financial performance with robust revenue growth and cash flow management, although some concerns exist around net profit margin volatility and ROE. Technical analysis suggests upward momentum, but high P/E ratio raises valuation concerns. Corporate events indicate strategic growth and potential acquisition, enhancing future prospects. Overall, the stock is well-positioned but with some valuation reservations.
To see Spark’s full report on GB:NIOX stock, click here.
NIOX Group plc, a company listed on the AIM market, has issued 363,006 new ordinary shares to its Executive Directors as part of its Deferred Share Bonus Plan. This issuance, related to the 2022 financial year’s annual bonus, follows the release of the company’s year-end results and marks the end of its closed period. The new shares are part of an existing block admission and align with the company’s remuneration policy, which defers a portion of bonuses for two years. This move reflects NIOX’s commitment to aligning executive incentives with shareholder interests, potentially impacting the company’s stock liquidity and executive shareholding structure.
NIOX Group PLC reported a 14% revenue growth to £41.8 million for the year ended 31 December 2024, with a 21% increase in adjusted EBITDA to £13.8 million. The company announced a proposal from Keensight Capital for a potential acquisition, though discussions are preliminary. Operationally, NIOX saw a 19% increase in NIOX® FeNO tests sold and is on track to launch the NIOX PRO® device in Q4 2025. The company is expanding its manufacturing capacity and distributor network, with plans to return 80% of free cash flow to shareholders, reflecting strong financial health and strategic growth initiatives.
Niox Group PLC, a UK-based company, has announced a change in its financial instrument holdings, with Spreadex LTD increasing its voting rights through financial instruments to 3.0694%. This adjustment reflects a rise from the previous 2.238264% and indicates a strategic positioning by Spreadex LTD, a regulated provider of spread betting and CFD trading, to potentially influence Niox Group’s decision-making processes. This development may impact stakeholders as it suggests a shift in the control dynamics within the company.
Niox Group PLC, a UK-based company, has announced a change in the voting rights held by Danske Bank A/S. The bank, headquartered in Copenhagen, Denmark, has reduced its voting rights in Niox Group from 4.059295% to 3.43072%, as of March 24, 2025. This change reflects a disposal of voting rights, potentially impacting the company’s shareholder dynamics and market perception.
NIOX Group Plc has received a revised proposal from Keensight Capital for a potential cash offer to acquire the company at 81 pence per share. The board is considering the offer and has allowed Keensight to conduct due diligence, though discussions are still in the preliminary stages. The company is also exploring other potential offers to maximize shareholder value.
NIOX Group Plc has received a revised proposal from Keensight Capital for a potential cash offer to acquire the company at 81 pence per share, following a previous offer of 78 pence per share. The board is considering the proposal, which is subject to due diligence, and has also initiated a private sale process to explore other potential offers, though no firm offers have been made yet.
Niox Group PLC, a part of the pharmaceutical industry, specializes in products and services related to healthcare, with a focus on diagnostics for respiratory conditions. The recent notification indicates a change in the voting rights, with Richard Griffiths and controlled holdings reducing their stake from 11.90% to 9.83% in Niox Group PLC. This adjustment in shareholding may impact the company’s governance and decision-making processes, potentially influencing its strategic direction.